Shattuck Labs, a clinical-stage biotechnology company, reported a net loss of $87.3 million for the year ended December 31, 2023, compared to a net loss of $101.9 million for the previous year. The company has not generated revenue from product sales and has funded operations through equity offerings, debt financings, and collaboration agreements. Research and development expenses decreased by 10.4% to $74.3 million, primarily due to reduced costs in manufacturing clinical trial materials, offset by increased clinical trial costs for SL-172154. General and administrative expenses also decreased by 8.4% to $19.3 million. Shattuck Labs has not declared or paid dividends on its capital stock and intends to retain future earnings to finance operations and expansion. The company's cash and cash equivalents and investments totaled $130.6 million as...Show More

Shattuck Labs, a clinical-stage biotechnology company, reported a net loss of $87.3 million for the year ended December 31, 2023, compared to a net loss of $101.9 million for the previous year. The company has not generated revenue from product sales and has funded operations through equity offerings, debt financings, and collaboration agreements. Research and development expenses decreased by 10.4% to $74.3 million, primarily due to reduced costs in manufacturing clinical trial materials, offset by increased clinical trial costs for SL-172154. General and administrative expenses also decreased by 8.4% to $19.3 million. Shattuck Labs has not declared or paid dividends on its capital stock and intends to retain future earnings to finance operations and expansion. The company's cash and cash equivalents and investments totaled $130.6 million as of December 31, 2023, which is expected to fund operations into 2026. Shattuck Labs' business development includes a clinical trial collaboration with ImmunoGen and an agreement with Ono Pharmaceutical for autoimmune and inflammatory diseases. The company's future plans involve advancing the clinical development of SL-172154, initiating clinical trials for additional product candidates, and exploring further collaborations.